Board Meeting Details

The Board of Directors meeting was held on Wednesday, 12th August, 2026, commencing at 1:00 PM and concluding at 1:40 PM.

Key Financial Results - Standalone (INR in Lakhs)

Quarter Ended 30th June, 2026 (Unaudited)

  • Revenue from operations: ₹1,417.81
  • Other income: ₹68.34
  • Total revenue: ₹1,486.15
  • Total expenses: ₹1,345.71
  • Profit before tax: ₹140.45
  • Tax expense: ₹34.01 (Current tax: ₹32.65, Deferred tax: ₹1.36)
  • Profit after tax: ₹106.44
  • Earnings Per Share (Basic): ₹0.74
  • Earnings Per Share (Diluted): ₹0.62
  • Paid up Equity Share Capital: ₹1,434.59 (Face Value of ₹10 each)

Comparative Performance

  • Revenue growth: 90.3% YoY (₹745.23 lakhs in Q1 FY26)
  • Profit after tax growth: 53.8% YoY (₹69.22 lakhs in Q1 FY26)

Key Financial Results - Consolidated (INR in Lakhs)

Quarter Ended 30th June, 2026 (Unaudited)

  • Revenue from operations: ₹1,674.88
  • Other income: ₹41.08
  • Total revenue: ₹1,715.96
  • Total expenses: ₹1,519.52
  • Profit before tax: ₹199.93
  • Tax expense: ₹49.09 (Current tax: ₹43.75, Deferred tax: ₹5.34)
  • Total comprehensive income: ₹150.83
  • Attributable to shareholders: ₹130.79
  • Attributable to non-controlling interests: ₹20.04
  • Earnings Per Share (Basic): ₹0.91
  • Earnings Per Share (Diluted): ₹0.76
  • Paid up Equity Share Capital: ₹1,434.59 (Face Value of ₹10 each)

Comparative Performance

  • Revenue growth: 56.4% YoY (₹1,071.15 lakhs in Q1 FY26)
  • Profit attributable to shareholders growth: 43.1% YoY (₹91.42 lakhs in Q1 FY26)

Business Segments

The Group operates under two reportable segments:

1. Specialty & Fine Chemicals

  • Q1 FY27 Revenue: ₹1,525.32 lakhs
  • Q1 FY27 Segment Results: ₹98.86 lakhs

2. Logistics Services (commenced operations in current financial year)

  • Q1 FY27 Revenue: ₹149.56 lakhs
  • Q1 FY27 Segment Results: ₹28.67 lakhs

Entity Structure

The consolidated results include:

  • Parent: Eiko Lifesciences Limited
  • Subsidiaries: Eiko Scientific Solutions LLP (Wholly Owned LLP), Eikovivify Logistics Private Limited
  • Associates: Reflux Pharmaceuticals Private Limited, SSM Formulations Private Limited

Auditor Review

The financial results were reviewed by P SV Jain & Associates, Chartered Accountants (Firm Registration No.: 131505W), who issued an unmodified review conclusion. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 issued by ICAI.

Limited Review Scope Note

The auditors noted they did not review the interim financial results of 2 associates included in the consolidated statement, which reflected total revenues of ₹607.10 lakhs and net profit after tax of ₹12.64 lakhs for the quarter. These were reviewed by other auditors.